Lumbar spine bone mineral density in diabetic children with recent onset
- PMID: 9838239
- DOI: 10.1159/000023273
Lumbar spine bone mineral density in diabetic children with recent onset
Abstract
To detect early abnormalities in bone mineralization, the lumbar spine bone mineral density (BMD) of diabetic children with a diabetes onset of less than 5 years and treated with a similar insulin treatment scheme was measured at the level of the lumbar spine by dual-energy X-ray absorptiometry (DEXA), a most sensitive technique for detecting osteopenia in children. Fifteen male and 8 female children and adolescents (mean age +/- SD: 12.5+/-3.7 years), 1-5 years after the clinical onset of their diabetes, were studied. Measurements of the lumbar spine (L1-L4) BMD, expressed in gHA/cm2 and as a z-score for age, were performed with a commercial DEXA apparatus (Hologic QDR 1000 W, Hologic Inc., Waltham, USA). Calcium-phosphorus metabolism was studied by measuring the circulating levels of calcium, phosphorus, alkaline phosphatase, osteocalcin, 25-OH-vitamin D and parathyroid hormone and the urinary excretion of calcium and phosphorus. The mean BMD of the studied group was 0.75 (0.16) gHA/cm2 giving a mean z-score of -0.31+/-0.95. Only 1 of the patients had a BMD lower than -2 SD. No sex difference in BMD z-score existed. BMD SD was positively correlated with height SD (R = 0.56, p < 0.005), but not with the age of the patients, the duration of the disease, the degree of metabolic control or the studied parameters of the calcium-phosphorus metabolism. In conclusion, diabetic children have a normal lumbar spine BMD during the first years of the disease, when a good metabolic control and no abnormalities in the calcium-phosphorus metabolism are present. As in normal children, areal BMD by DEXA is highly dependent on the body height, necessitating corrections if abnormalities in skeletal growth or pubertal development exist.
Similar articles
-
Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology.J Endocrinol Invest. 2000 May;23(5):295-303. doi: 10.1007/BF03343726. J Endocrinol Invest. 2000. PMID: 10882147
-
BONE MINERAL DENSITY IN CHILDREN WITH IDIOPATHIC HYPERCALCIURIA.Dev Period Med. 2015 Jul-Sep;19(3 Pt 2):356-61. Dev Period Med. 2015. PMID: 26958681
-
Decreased lumbar spine bone mass and low bone turnover in children and adolescents with insulin dependent diabetes mellitus followed longitudinally.J Pediatr Endocrinol Metab. 1998;11(3):413-9. doi: 10.1515/jpem.1998.11.3.413. J Pediatr Endocrinol Metab. 1998. PMID: 11517957
-
Evaluation of bone metabolism in children with cystic fibrosis.Bone. 2021 Jun;147:115929. doi: 10.1016/j.bone.2021.115929. Epub 2021 Mar 16. Bone. 2021. PMID: 33737192 Review.
-
A Scoping Review of the Recent Clinical Practice Regarding the Evaluation of Bone Mineral Density in Children and Adolescents with Neuromuscular Diseases.Medicina (Kaunas). 2023 Feb 8;59(2):312. doi: 10.3390/medicina59020312. Medicina (Kaunas). 2023. PMID: 36837513 Free PMC article.
Cited by
-
Beyond glycemic control in diabetes mellitus: effects of incretin-based therapies on bone metabolism.Front Endocrinol (Lausanne). 2013 Jun 18;4:73. doi: 10.3389/fendo.2013.00073. eCollection 2013. Front Endocrinol (Lausanne). 2013. PMID: 23785355 Free PMC article.
-
Lower bone mineral density in children with type 1 diabetes is associated with poor glycemic control and higher serum ICAM-1 and urinary isoprostane levels.J Bone Miner Metab. 2009;27(5):598-604. doi: 10.1007/s00774-009-0076-4. Epub 2009 Apr 17. J Bone Miner Metab. 2009. PMID: 19373518
-
Bone mass and structure in adolescents with type 1 diabetes compared to healthy peers.Osteoporos Int. 2009 Aug;20(8):1401-6. doi: 10.1007/s00198-008-0810-0. Epub 2008 Dec 13. Osteoporos Int. 2009. PMID: 19083073
-
Osteoporosis and diabetes mellitus.Rev Endocr Metab Disord. 2004 Aug;5(3):261-8. doi: 10.1023/B:REMD.0000032415.83124.20. Rev Endocr Metab Disord. 2004. PMID: 15211098 Review. No abstract available.
-
Osteoporosis in children and adolescents: etiology and management.Paediatr Drugs. 2005;7(5):295-323. doi: 10.2165/00148581-200507050-00003. Paediatr Drugs. 2005. PMID: 16220996 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials